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Objective:
 
 The objective was to assess the impact of differ-
ent levels of risk of disease on a woman’s preferences for
health states. Women were provided with health scenarios
incorporating different levels of lifetime risks for breast
cancer, hip fracture, and coronary heart disease (CHD). In
this way, we were able to determine the incremental effect
of changes in risks of each disease on preference values.
 
Methods and Data:
 
 Preference values and utility scores
were obtained for six health scenarios by both the feel-
ing thermometer (FT) and standard gamble (SG) meth-
ods. Scenarios presented the different lifetime risks of
CHD, breast cancer, and hip fracture associated with
and not associated with long-term use of hormone re-
placement therapy (HRT) and raloxifene. Risks of
breast cancer were based on perceived risks and popu-
lation risks. The sample population consisted of 40
healthy female volunteers aged between 45 and 65
years randomly selected from the Ottawa-Carleton dis-
trict.
 
Results:
 
 Based on their perceived risk of breast cancer,
the women had higher value scores for the raloxifene
risk profile than for both HRT (
 
p
 
 
 

 
 .002) and no ther-
apy (
 
p
 
 
 

 
 .003), with similar results for analyses based
on population risks and from utility scores. Regression
analysis showed that the risk of breast cancer (
 
p
 
 
 

 
.001)
was the only disease risk that was statistically signifi-
cantly associated with women’s preferences.
 
Conclusions:
 
 Women had significant preferences over
the different risk profiles, primarily due to the incre-
mental effect on changes in values for the risk of breast
cancer. Therefore, studies evaluating therapies for os-
teoporosis should consider patient preferences for living
with different risk profiles.
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Introduction
 
In assessing the potential utility gain from therapy,
the general model is to obtain utility scores for po-
tential life events and to then calculate an ex-
pected utility value based on the probability of
their occurrence. However, such models fail to in-
clude the potential effect that the burden of risk
may have on utility scores.
A woman’s decision whether to take hormone
replacement therapy (HRT) or other interventions
for osteoporosis is influenced by her perception of
the risks of diseases such as coronary heart disease
(CHD) and breast cancer and her preferences re-
garding such risks [1–3]. Choices are influenced
by individual preferences for living with the vari-
ous diseases. However, before a woman experi-
ences any of the diseases, she may have concerns
with respect to the risk of living with potential dis-
ease states in the future. Thus, a woman’s choice
of therapy may be influenced by the effects of util-
ity on the level of risk of developing disease.
Because resources for health care are scarce, it
has become increasingly necessary to demonstrate
the cost-effectiveness of different therapies [4]. To
fully assess cost-effectiveness of health-care inter-
ventions, it is necessary to account for patient
preferences for potential health states [5]. A num-
ber of economic analyses of therapies for os-
teoporosis have been conducted, but few have in-
corporated individual preferences for health states
related to breast cancer, hip fracture, and CHD
[6–13]. Furthermore, none of the evaluations has
incorporated the value that women place on living
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with different risks of disease on their preferences
for their current health state.
The study was designed to elicit women’s pref-
erence values for health states associated with liv-
ing with different levels of lifetime risks for breast
cancer, hip fracture, and CHD. Valuations reflect
the women’s preference for the alternative risk pro-
files. Thus, the assumption of the model on which
this study is based is that women will have explicit
preferences for health states, not only in relation
to their current health, but also with respect to the
lifetime risk of specific diseases.
The different scenarios included HRT, no ther-
apy, and raloxifene, a selective estrogen receptor
modulator that is approved for the treatment of os-
teoporosis and may have a protective effect against
CHD and breast cancer. The objectives of the study
were to identify which of the risk profiles women
preferred and which individual characteristics af-
fected their preferences for the various health states.
In addition, the study was designed to determine
the incremental effects of a change in risk of develop-
ing each disease on women’s preferences for health
states. The study was approved by the Ottawa Civic
Hospital Research Ethics Committee.
 
Methods
 
Preference Assessments
 
Preference assessments involve the valuation of
health-state scenarios. Alternative methods of as-
sessment allow subjects to judge the relative im-
portance of different dimensions of health in an
explicit manner. There exist a variety of different
approaches to preference assessments that allow
for the valuation of health scenarios on a scale
from zero to one, where zero represents death and
one represents perfect or ideal health.
There are two main forms of preference values:
value scores and utility scores [4,14]. Value scores
are generated under conditions of certainty and are
based on the principles of psychological scaling. Util-
ity scores require subjects to make choices concern-
ing health states that are uncertain. The use of utility
scores is based on the axioms of the von Neumann-
Morgenstern utility theory, considered to be the gold
standard in preference assessments for the allocation
of health-care resources. In practice, utility scores
tend to be higher than value scores, which demon-
strates people’s risk aversion [15].
Respondents were interviewed using a standard-
ized interview script, and interviews took an average
of 40 minutes to complete. A single person trained
in interviewing techniques for preference-value elici-
tation conducted interviews. The interview format
mirrored previous interviews employed for utility
elicitation and was pretested in a convenience sam-
ple of five women who met the study inclusion crite-
ria. The pretest confirmed the feasibility of the pro-
posed interview. Value and utility scores for six
health scenarios were obtained by means of a feeling
thermometer (FT) and standard gambles (SG) from
each respondent (Fig. 1) [16].
The FT required that respondents rate each sce-
nario on a scale from 0 to 100, with 0 represent-
ing death and 100 representing the best imagin-
able health state. Respondents were provided with
cards describing each of the health scenarios and
arrows representing each health state. Respon-
dents were then asked to place the arrows on the
graded FT scale. None of the scenarios was rated
worse than death by any of the respondents.
The SG method required that respondents choose
between one specific outcome of one of the health
scenarios or a gamble between a chance for per-
fect health and another state. Respondents were
shown a chance board detailing the probability, in
terms of percentage, of achieving each health state
for each successive gamble. The least-preferred
scenario was the gamble between perfect health
and death. The gamble for other scenarios was be-
tween perfect health and the scenario representing
the best possible health state that was less than
perfect. Because utility scores were based on true
incremental values, this may have increased mea-
surement error.
 
Calculation of Utility Scores
 
The six scenarios evaluated were:
1. population risk of breast cancer with popula-
tion risk of fracture and CHD;
2. scenario 1 with all risks adjusted for the effects
of long-term use of HRT;
3. scenario 1 with all risks adjusted for the effects
of long-term use of raloxifene;
4. perceived risk of breast cancer with population
risk of fracture and CHD;
5. scenario 4 with all risks adjusted for the effects
of long-term use of HRT; and
6. scenario 4 with all risks adjusted for the effects
of long-term use of raloxifene.
Respondents were informed that health states
would last their entire lives with the possibility of
disease occurring at any point. Actual drugs were
not identified, but were referred to as “drug A”
and “drug B.” Thus, the values that a respondent
placed on a scenario reflected her preference for
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the risk profile contained within a given health sce-
nario and any preference over long-term drug ther-
apy. Also, values were unlikely to be influenced by
women’s past experience on related therapies.
 
Sample Size
 
The required study sample size was obtained by
focusing on an acceptable precision of the estimate
for preference values. Based on previous experi-
ence, we assumed that the range of utility values
for the relatively healthy states that were being
evaluated would be no greater than 0.5, and that a
difference in utility values of 0.05 between scenar-
ios would be meaningful. We conducted a ran-
dom-number-generation exercise based on con-
straining score values between 0.5 and 1 for
different numbers of women to determine the
sample size required to detect a 0.05 difference in
values with a power of 80% at a 5% level of sig-
nificance. Based on 200 random samples, a sample
size of 40 participants was the maximum sample
size required to detect the necessary differences.
The chosen sample size has less than 80%
power of detecting differences for the analysis of
scores based on respondent characteristics. Given
this, the results of the analysis by respondent char-
acteristics should be treated with caution.
 
Study Sample
 
The target population for the study was healthy
women aged between 45 and 65 years. The sample
population consisted of female volunteers drawn
from the Ottawa-Carleton district at random.
Forty healthy female volunteers were drawn
from a previous telephone survey of 120 women
aged between 45 and 65 years identified by ran-
dom-digit dialing. The telephone survey involved
interviewing the women with respect to their de-
mographic characteristics, personal risk factors,
knowledge of breast cancer, general health, and
level of anxiety. Demographic and other charac-
teristics of the 40 women are detailed in Table 1.
 
Calculation of Utility and Value Scores
 
The value score for each health state (V
 
i
 
) was cal-
culated by dividing the score on the FT by 100.
The SG was used to elicit utility scores (U
 
i
 
) for
scenarios 4, 5, and 6. Respondents were first asked
Figure 1 Health states descriptions
*DD  respondent’s perceived lifetime risk of breast cancer; EE  DD  13/11; FF  DD  6/11.
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to rate the health state they considered worst of
the three during the rating scale exercise (H
 
w
 
).
They were given a choice between remaining in
that health state or taking a gamble with a chance
of returning to a preferred state (perfect health)
but with a risk of having an immediate and pain-
less death. The probability of death was adjusted
by a ping-pong process whereby respondents con-
sidered first a gamble with a high risk of the pre-
ferred state and then a gamble with the same risk
of death. The process was repeated until the re-
spondent’s point of indifference was obtained.
The utility score for this health state was calcu-
lated according to the following formula:
This process was repeated for the other two health
states but with the gamble involving a risk of be-
ing in either the preferred health state or the least
preferred of the health states (H
 
w
 
). The utility
scores for further health states were calculated as
follows:
Uw 1 indifference probability of death–( )=
 
To reduce respondent burden, utility scores for
scenarios 1, 2, and 3 were not calculated directly,
but were estimated by adjusting preference scores
by the respondent’s revealed risk preference ob-
tained from analysis of utility scores and value
scores for scenarios 4, 5, and 6. For each respon-
dent, the utility scores for scenarios 1, 2, and 3
were obtained using the formula:
A similar process was then used to elicit utility
scores for scenarios 2 and 3.
 
Analysis
 
The analysis focused on three issues: 1) compari-
son of value and utility scores between scenarios;
2) effect of respondent characteristics on values;
and 3) determination of the effect of incremental
changes in risk for each disease.
The statistical significance of differences between
value and utility scores for each scenario and be-
tween scenarios was assessed by paired 
 
t
 
-tests.
The effect of the following factors on women’s
values for each scenario was assessed: perceived
risk of breast cancer, age, education, anxiety with
respect to breast cancer, frequency of mammogra-
phy, menopausal status, and current health state.
Either analyses of variance or 
 
t
 
-tests were used to
assess the statistical significance of each character-
istic.
To identify the incremental effect of the respon-
dents’ risk of disease on valuations, regression
analyses were conducted. Valuations for each re-
spondent for the six scenarios were combined to
obtain 240 dependent variables. Explanatory vari-
ables were the risks of disease within each sce-
nario and a dummy variable for each of the 40 re-
spondents.
 
Results
 
Comparison of Values for Scenarios
 
The analysis in which women’s perceived risk of
developing breast cancer was incorporated yielded
higher mean utility scores for the risk profile associ-
ated with raloxifene (
 

 
 0.85) than for both HRT
(
 

 
 0.78) and no therapy (
 

 
 0.78) (Table 2). The dif-
ferences between raloxifene and no therapy (
 
p
 
 
 

Ul Uw 1 Uw–( )+=
 1 indifference probability of Hw–( )×
Ui 1 1 Vi–( )
r( ) where–=
r 1 Ui 3+–( )log 1 Vi 3+–( )log⁄=
 
Table 1
 
Demographic characteristics of sample
 
Characteristics n (%)
Education:
Some high school 3 (7.5)
Completed high school 8 (20)
Some college 15 (37.5)
Some university 14 (35)
Do you still have periods?
Yes 13 (32.5)
In general would you say your health is:
Excellent/very good 30 (75)
Good/fair/poor 9 (22.5)
Don’t know 1 (2.5)
Do you know people who have had breast cancer?
Yes 37 (92.5)
Have you ever been told by a doctor or health 
professional that you had any type of cancer?
Yes 4 (10)
Have you had a mammograph less than 2 years ago?
Yes 26 (65)
If discovered early and treated with the best available 
medical treatment, how life threatening do you think 
beast cancer is?
Not at all/not very 12 (30)
Somewhat/very 24 (60)
Don’t know 4 (10)
Perception of lifetime risk of breast cancer
0–10% 6 (15)
11–20% 5 (12)
21–30% 6 (15)
31–40% 5 (12)
41–50% 9 (22)
51–60% 5 (12)
61–70% 2 (5)
71–80% 2 (5)
How often do you worry about getting breast cancer:
Never/hardly ever 17 (42.5)
A little bit/some time/all the time 23 (57.5)
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.002) and raloxifene and HRT (
 
p
 
 
 

 
 .003) were
statistically significant at the 5% level (Table 3).
Based on the population risk of developing
breast cancer, women had the same ordering of
utility scores between raloxifene (
 

 
 0.94), HRT
(
 

 
 0.92), and no therapy (
 

 
 0.88) (Table 2). The
difference between raloxifene and no therapy (
 
p
 
 
 

 
.001) was statistically significant. The differences
between raloxifene and HRT (
 
p
 
 
 

 
 .152) and HRT
and no therapy (
 
p
 
 
 

 
 .051) were not statistically
significant.
Results based on analysis of value scores were
similar, although women demonstrated risk aver-
sion with higher utility scores than value scores
for each scenario.
 
Respondent Characteristics
 
As would be expected, women’s perceived risk of
breast cancer was a significant determinant of util-
ity scores and value scores for scenarios 4, 5, and
6. Perceived risks were not significant determinants
of utility or value scores for scenarios 1, 2, and 3.
None of the other respondent characteristics had
a statistically significant effect on utility or value
scores.
 
Incremental Effect of Risk of Disease
 
In the regression model, the respondent’s risk of
breast cancer was a significant determinant of
both value and utility scores (
 
p
 
 < 0.001 in both
analyses) (Table 4). The risk of heart disease (
 
p
 
 
 

 
0.571 and 0.689) and the risk of hip fracture (
 
p
 
 
 

 
0.413 and 0.864) were not significant determi-
nants of either value or utility scores.
 
Conclusions
 
In general, women favored the risk profile associ-
ated with raloxifene compared with that of HRT.
Regression analysis confirmed that women’s pref-
 
Table 2
 
Value and utility scores by scenario (N 
 

 
 40)
 
Scenario
Mean value
scores (range)
Mean utility
scores (range)
Population risks No therapy 0.649 (0.60, 0.70) 0.883 (0.84, 0.93)
HRT 0.696 (0.66, 0.73) 0.920 (0.88, 0.96)
Raloxifene 0.728 (0.68, 0.77) 0.935 (0.90, 0.97)
Perceived risks No therapy 0.486 (0.43, 0.54) 0.776 (0.70, 0.85)
HRT 0.463 (0.40, 0.53) 0.776 (0.69, 0.87)
Raloxifene 0.605 (0.54, 0.67) 0.851 (0.78, 0.92)
 
Table 3
 
Difference in values between scenarios according to method (N 
 

 
 40 pairs)
 
Comparators Mean value scores (95% CI) Mean utility scores (95% CI)
Population risks HRT over no therapy 0.046 (0.00, 0.09) 0.036 (0.00, 0.07)
Raloxifene over no therapy 0.079 (0.04, .12) 0.052 (0.02, 0.08)
Raloxifene over HRT 0.033 (0.00, .07) 0.015 (
 

 
0.01, 0.04)
Perceived risks HRT over no therapy
 

 
0.024 (
 

 
0.06, .01) 0.000 (
 

 
0.04, .04)
Raloxifene over no therapy 0.119 (0.08, 0.16) 0.075 (0.03, 0.12)
Raloxifene over HRT 0.142 (0.10, 0.18) 0.075 (0.03, 0.12)
 
Table 4
 
OLS regression results*
 
Value scores Utility scores
Coefficient
 
P
 
-value Coefficient
 
P
 
-value
Constant 0.806 (0.000) 1.215 (0.000)
risk of CHD (%) 0.006 (0.571)
 

 
0.004 (0.689)
risk of breast cancer (%)
 

 
0.006 (0.000)
 

 
0.004 (0.000)
risk of hip fracture (%)
 

 
0.025 (0.413) 0.005 (0.864)
I
 
1
 
0.111 (0.069) 0.002 (0.755)
I
 
2
 

 
0.148 (0.016)
 
0.003 (0.656)
I3 0.002 (0.747) 0.004 (0.533)
I4 0.111 (0.069) 0.010 (0.876)
I5 0.009 (0.148) 0.004 (0.548)
I6 0.005 (0.392) 0.586 (0.000)
I7 0.002 (0.769) 0.006 (0.357)
I8 0.144 (0.019) 0.004 (0.548)
I9 0.163 (0.008) 0.004 (0.540)
I10 0.207 (0.001) 0.115 (0.068)
I11 0.159 (0.010) 0.324 (0.000)
I12 0.101 (0.098) 0.002 (0.755)
I13 0.001 (0.848) 0.100 (0.111)
I14 0.009 (0.136) 0.121 (0.055)
I15 0.003 (0.623) 0.004 (0.548)
I16 0.008 (0.164) 0.009 (0.146)
I17 0.002 (0.769) 0.356 (0.000)
I18 0.008 (0.188) 0.004 (0.533)
I19 0.271 (0.000) 0.494 (0.000)
I20 0.010 (0.107) 0.007 (0.273)
I21 0.144 (0.018) 0.001 (0.876)
I22 0.010 (0.114) 0.224 (0.000)
I23 0.004 (0.482) 0.353 (0.000)
I24 0.193 (0.002) 0.256 (0.000)
I25 0.007 (0.279) 0.144 (0.023)
I26 0.131 (0.032) 0.119 (0.059)
I27 0.196 (0.001) 0.178 (0.005)
I28 0.205 (0.001) 0.004 (0.584)
I29 0.170 (0.006) 0.488 (0.000)
I30 0.003 (0.655) 0.006 (0.350)
I31 0.164 (0.008) 0.009 (0.139)
I32 0.000 (0.956) 0.190 (0.003)
I33 0.163 (0.008) 0.124 (0.050)
I34 0.007 (0.275) 0.337 (0.000)
I35 0.185 (0.003) 0.007 (0.298)
I36 0.139 (0.024) 0.235 (0.000)
I37 0.180 (0.003) 0.005 (0.461)
I38 0.001 (0.808) 0.001 (0.830)
I39 0.002 (0.730) 0.004 (0.540)
R2 0.767 0.778
* Ii are dummy variables to control for differences between respondents.
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erences for the scenario associated with raloxifene
were primarily based on the incremental effect of
change in the risk of developing breast cancer.
Thus, compared with HRT, the reduction in
breast cancer risk with raloxifene was a suitable
trade-off for the higher risks of hip fracture and
CHD associated with raloxifene. These results im-
ply that the women had limited concern over the
risks of CHD and fracture but significant concern
over the risk of breast cancer.
The statistical significance of a number of dummy
variables for the individual women demonstrates
that, although the women seemed to express simi-
lar relative values for each scenario, absolute val-
ues were quite different. This lack of homogeneity
in absolute values confirms that individual women
weigh concerns over living with the risks of dis-
ease differently when making treatment choices.
Women whose perceived risk for developing
breast cancer was greater than that of the popula-
tion, rated scenarios based on perceived risks
lower than those who believed they had a lower
risk for breast cancer. They also rated the three
scenarios based on perceived risks lower than the
scenarios based on population risks. Both these
findings can be seen to support the validity of the
techniques adopted.
No demographic or other characteristics of the
women appeared to act as determinants of the
preference values they placed on the different risk
profiles, although the ability of our study to con-
firm this finding is limited. This finding need not
imply that demographic or other characteristics
do not act as determinants of treatment choice;
rather, they do not act as determinants of this par-
ticular factor that may affect treatment choice.
There are several caveats to our analysis. There
may be disagreement over the choice of top an-
chors identified as best imaginable health state
and perfect health. This problem, however, exists
with all analyses relating to value scores for health
states. The choice of anchors adopted in this study
is no more prone to such concerns than others and
is consistent with much of the previous literature.
Also, by using an incremental approach to ob-
tain utility values, there is risk related to the endo-
geneity of the values obtained. However, such
concerns have to be weighed against the desire to
obtain accurate results that reflect the subjective
value placed on health states, which the incremen-
tal approach is more likely to allow. The wide
range of incremental values obtained implies that
endogeneity was probably not a major factor.
In conclusion, a woman’s choice of therapy for
osteoporosis may be influenced by individual pref-
erences both for potential disease states and for
living with different risk profiles. Given our find-
ings, evaluations of alternative therapies for os-
teoporosis should consider not only the utility re-
lated to the potential disease states, but also
preferences for living with different risk profiles.
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